MacroCure raises $53.5 million in IPO

Israeli biotech regenerative medicine company MacroCure Ltd. (NASDAQ:MCUR) raised $53.5 million through the sale of 5.4 million shares at $10 in an IPO underwritten by Credit Suisse; Jefferies; Nomura; and Oppenheimer. The IPO priced valued MacroCure at $161.8 million. Last month, the company said it planned to sell 5.4 million shares at $13-$15.

MacroCure's CureXcell is in Phase III testing to treat diabetic foot ulcers and venous leg ulcers, with data slated for 2H15. The suspension containing activated allogeneic white blood cells isolated from the peripheral blood of healthy donors is already marketed in Israel. ...